Ametris

Clinical Trial Digital Health Technologyametris.com

Company typePrivate
Founded2004
HeadquartersPensacola, United States
Headcount51–100
GTM typeB2B
OfferingSoftware

Ametris firmographics

Firmographics

Name: Ametris
Legal name: Ametris, LLC
Website: https://ametris.com
Company type: Private
Founded year: 2004
Operating status: Operating
Headcount range: 51–100 employees
Ownership category
akta.pro rank

Ametris industry classification

Industry

Product category: Clinical Trial Digital Health Technology
NAICS: Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Computer Systems Design Services (541512), Scientific Research and Development Services (5417)
SIC: Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry: Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG)
akta.pro secondary industries: Clinical Trial Analytics, Risk-Based Monitoring (RBM) & Quality Management (HLACAOAI), Clinical Trial Management Systems (CTMS) (HLACAOAD), Safety/Pharmacovigilance (PV) & Clinical Safety Systems (HLACAOAH)

Keywords

Digital health technology
Clinical trial wearables
Digital biomarkers
Remote patient monitoring
Actigraphy devices

Where Ametris is headquartered

Location

Headquarters

HQ city: Pensacola
HQ country: United States
HQ region: North America

Offices1 record

Markets served

Ametris business model

Business model

GTM type: B2B
Offering type: Software
Cost components: Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

Wearable Device Sales: Sale of FDA-cleared medical-grade wearable devices including ActiGraph LEAP, CentrePoint Insight Watch, and wGT3X-BT for use in clinical trials and academic research
Software Platform Subscription: Subscription access to CentrePoint platform for remote monitoring, data management, and analytics services
Regulatory Science Services: Data analytics and regulatory science consulting services to support digital endpoint development and regulatory submissions
DECODE Collaborations: Evidence-generation collaborations and exclusive biomarker IP licensing arrangements with pharmaceutical sponsors

Pricing tiers

Model	Billing	Price
Other	One time	Academic/Non-Profit Registration - Early Bird
Other	One time	Academic/Non-Profit Registration - Advance
Other	One time	Academic/Non-Profit Registration - Standard
Other	One time	Pharma/Industry Registration - Early Bird
Other	One time	Pharma/Industry Registration - Advance
Other	One time	Pharma/Industry Registration - Standard

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Ametris product offering

Product offering

Core offering

Ametris provides an end-to-end digital health technology solution for clinical trials, combining FDA 510(k)-cleared, medical-grade wearable devices (ActiGraph LEAP, CentrePoint Insight Watch, wGT3X-BT) with the scalable CentrePoint remote monitoring platform powered by the Ametris Connect ecosystem. The company sells hardware, software subscriptions, and data analytics/regulatory science services to pharmaceutical sponsors, biotech companies, CROs, and academic researchers to enable continuous, objective measurement of digital outcomes across therapeutic areas.

Product overview

Ametris (formerly ActiGraph) provides an end-to-end digital health technology (DHT) solution combining medical-grade wearable devices, the scalable CentrePoint® remote monitoring platform powered by Ametris Connect™, and full-service operational and scientific support. The portfolio includes the ActiGraph LEAP® and CentrePoint® Insight Watch FDA-cleared wearable devices, ActiLife® data analysis software, and the Algorithm Marketplace for validated digital measures. Solutions span digital outcomes including sleep, physical activity, gait and mobility, vital signs, and cardinal symptoms, supported by data analytics and regulatory science services across therapeutic areas including cardiology, dermatology, obesity, oncology, respiratory, rheumatology, immunology, and neurology.

Differentiator

Problem solved

Functional benefit

Products and services

CentrePoint® Platform Cloud-based data management platform for collecting, processing, and managing high-quality real-world data from wearable devices across clinical trials. Targeted at pharmaceutical sponsors and CROs running decentralized or hybrid clinical trials requiring centralized sensor data ingestion and management.
Ametris Connect™ Platform
CentrePoint® Insight Watch FDA-cleared, medical-grade wrist-worn wearable device with photoplethysmography (PPG) for continuous monitoring of vital signs, activity, and sleep in clinical trials. Used by pharmaceutical sponsors and academic researchers for remote vital sign monitoring.
ActiGraph LEAP® FDA-cleared medical-grade wrist-worn wearable device combining accelerometer and PPG sensors for comprehensive digital health measurements in clinical research. Targeted at pharmaceutical sponsors and CROs conducting clinical trials requiring validated multimodal sensing.
ActiGraph wGT3X-BT Research-grade actigraphy device for continuous monitoring of physical activity, sleep, and movement behaviors. Used by academic researchers and clinical trial sponsors for objective activity and sleep measurement.
ActiLife® Software platform for data analysis, processing, and management of actigraphy data from Ametris wearable devices. Sold primarily to academic researchers and clinical trial teams for offline and research-grade data processing.
Algorithm Marketplace Digital marketplace providing access to validated, regulatory-aligned algorithms for digital measures, enabling streamlined adoption in clinical development and regulatory submissions. Used by pharmaceutical sponsors and clinical trial teams to incorporate pre-validated digital endpoints into their studies.
DECODE (Digital Endpoint Collaboration to Accelerate Outcome Development) Precompetitive collaboration programs bringing together multiple pharmaceutical sponsors to develop and validate digital endpoints in specific therapeutic areas (Obesity, Nocturnal Scratch/dermatology, CRS/oncology). Generates shared evidence, exclusive biomarker IP for participants, and regulatory engagement support.

Quantifiable outcome

Combined eCOA and wearable platform reduces fragmented vendor approach in clinical trials
+1 more outcomes

Companies that use Ametris

Customer profile

Named customers13 records

Segments4 records

Ideal customer profiles3 records

Ametris technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Ametris partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

Eli LillycoreStrategic or Co-development PartnerDECODE: Obesity collaboration partner, working with Ametris on evidence generation and biomarker development for obesity therapeutics research
RochecoreStrategic or Co-development PartnerDECODE: Obesity collaboration partner, working with Ametris on evidence generation and biomarker development for obesity therapeutics research
Novo NordiskcoreStrategic or Co-development PartnerDECODE: Obesity collaboration partner, working with Ametris on evidence generation and biomarker development for obesity therapeutics research
AstraZenecacoreStrategic or Co-development PartnerDECODE: Obesity collaboration partner, working with Ametris on evidence generation and biomarker development for obesity therapeutics research
Takeda PharmaceuticalscoreStrategic or Co-development PartnerDECODE collaboration partner and conference participant; Head of Sensing and Measurement Ariel Dowling represents Takeda at ADDS events
ParexelcoreStrategic or Co-development PartnerPlatinum level sponsor of ADDS conference; Parexel's Scientific Data Organization enables clinical research with wearables and sensors, with Sensor Solutions Director Nathan Noakes presenting at ADDS events
IQVIAminorStrategic or Co-development PartnerPlatinum sponsor of ADDS events; IQVIA's Patient Centered Solutions team helps companies design clinical trials that accurately reflect patient experience using digital endpoints
Top 10 Global Pharma Companies (8 of top 10)coreStrategic or Co-development PartnerPartnerships with eight of the top ten global pharmaceutical companies through evidence-generation collaborations, exclusive biomarker IP licensing, and regulatory engagements
Top 25 R&D Spenders (20 of top 25)coreStrategic or Co-development PartnerPartnerships with twenty of the top 25 R&D spending organizations through evidence-generation collaborations, exclusive biomarker IP licensing, and regulatory engagements

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Ametris competitors and assessment

Company assessment

Emerging players

Evidation Health: Evidation Health operates a connected health platform that generates real-world evidence from wearables and sensors for health outcomes research. Comparable in wearable-derived digital measurement and digital biomarker development for pharma and life sciences customers.
Medable: Medable provides a decentralized clinical trial platform including eCOA, eConsent, and wearable/sensor data integration. Comparable in enabling pharma sponsors to operationalize DHT-enabled trials, though broader in scope than Ametris's wearable endpoint focus.
Cytel: Cytel provides clinical trial analytics, statistical software (East), and biostatistics services with growing focus on digital endpoint strategy. Comparable in supporting regulatory-accepted clinical trial endpoints and serving pharma R&D organizations.
PHAR (previously PhysIQ): PHAR (formerly physIQ) provides continuous biosensor data analytics and AI-driven digital biomarkers for clinical trials and healthcare. Comparable as a wearable/sensor digital biomarker platform serving pharma sponsors with regulatory-grade endpoints.

Broad incumbents

Medidata (Dassault Systèmes): Medidata provides the Rave clinical cloud platform for eCOA, EDC, and decentralized clinical trials, and has been expanding into sensors/wearables integration. Comparable as a large incumbent in clinical trial data capture with growing DHT ambitions overlapping Ametris's wearable data platform.
IQVIA: IQVIA is the world's largest CRO with a Patient Centered Solutions team that includes eCOA, digital endpoints, and wearable sensor strategy for clinical trials. Comparable as both a customer/partner and a broad incumbent offering overlapping digital endpoint capabilities.
Signant Health: Parent company since May 2026, Signant Health is the leader in eCOA (electronic clinical outcome assessments) for clinical trials. Directly comparable as the eCOA counterpart to Ametris's wearable-based digital outcome measures, with overlapping pharma/biotech customer base and clinical trial technology focus.

Direct peers

Clario: Clario (formed from the merger of ERT and CRF Health/Bioclinica) is a direct competitor in clinical trial technology, offering eCOA, cardiac safety, imaging, and increasingly wearable/respiratory sensor solutions. Most directly comparable end-to-end clinical trial technology peer with overlapping enterprise pharma customers.
VivoSense: VivoSense develops wearable sensor-based digital clinical outcome assessments and validated digital endpoints for clinical trials, with a focus on regulatory-grade evidence. Closest direct peer to Ametris in the digital biomarker / wearable endpoint space for pharma trials.
Koneksa Health: Koneksa Health provides digital biomarkers for clinical research using wearables and connected sensors, with a focus on respiratory, oncology, and rare disease trials. Comparable as a digital biomarker specialist serving pharma sponsors with overlapping therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Ametris compliance and trust

Trust signal

Compliance7 records

Ametris financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ametris leadership team

Management profile

Number of profiles

Profiles2 records

Ametris funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ametris M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ametris

What does Ametris do?

Is Ametris a public or private company?

Ametris is a private company. It is classified as corporate owned and is currently operating.

When was Ametris founded?

Ametris was founded in 2004. It employs 51 to 100 people.

Where is Ametris based?

Ametris is headquartered in Pensacola, United States, in the North America region.

How does Ametris make money?

Four revenue lines are on record. Wearable Device Sales are the primary driver. The others are software Platform Subscription, regulatory Science Services and DECODE Collaborations.

Who are Ametris's main competitors?

Emerging players on record are Evidation Health, Medable, Cytel and PHAR (previously PhysIQ). Broad incumbents are Medidata (Dassault Systèmes), IQVIA and Signant Health. Direct peers are Clario, VivoSense and Koneksa Health.

Does Ametris have an API?

No public API is recorded for Ametris.

What industry is Ametris in?

Ametris's product category is Clinical Trial Digital Health Technology. Its primary akta.pro industry code is HLACAFAG, Medical-Grade Device Connectivity & Device Management (MDM), with a secondary code of HLACAOAI, Clinical Trial Analytics, Risk-Based Monitoring (RBM) & Quality Management. Its NAICS code is 334510 and its SIC code is 3845.